What Agios Pharmaceuticals, Inc. does.

We are a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities, collaborating to develop and deliver innovative medicines with the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve.

The lead product candidate in our portfolio, mitapivat, is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. Mitapivat is approved in the United States by the U.S. Food and Drug Administration, or FDA, under the brand name AQVESME™ for the treatment of anemia in adults with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia and in Saudi Arabia under the brand name PYRUKYND® for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. Mitapivat is also approved under the brand name PYRUKYND® in the United States by the FDA for the treatment of hemolytic anemia in adults with PK deficiency and in the European Union, or EU, and Great Britain for the treatment of PK deficiency in adults.

Revenue and profit, by fiscal year.

More on AGIO.

• Agios Pharmaceuticals, Inc. summary
• Agios Pharmaceuticals, Inc. financial statements
• Agios Pharmaceuticals, Inc. key metrics
• Agios Pharmaceuticals, Inc. health scores and style box
• Agios Pharmaceuticals, Inc. earnings
• Agios Pharmaceuticals, Inc. dividends
• Agios Pharmaceuticals, Inc. valuation
• Agios Pharmaceuticals, Inc. ownership and insiders
• Agios Pharmaceuticals, Inc. peers

Figures from Agios Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.